Table 1.
Clinical charactersitics and baseline values of the study population
| CHP patients | Normal controls | ||
|---|---|---|---|
| n | 18 | 12 | |
| Ischaemic/dilated (n) | 11/7 | ||
| Sex: male/female | 14/4 | 8/4 | |
| Age (years) | 62.1 ± 3.18 | 60.3 ± 3.65 | |
| Weight (kg) | 78.2 ± 2.92 | 75.4 ± 4.2 | |
| Exercise duration (min) | 6.9 ± 0.8 | 10.8 ± 0.9* | |
| LVEF (%) | 30.8 ± 3.24 | ||
| Peak VO2 (ml min−1 kg−1) | 18.1 ± 1.64 | 25.6 ± 2.51* | |
| VE at rest (1 min−1) | 13.9 ± 1.08 | 14.5 ± 1.77 | |
| VO2 at rest (1 min−1) | 0.4 ± 0.03 | 0.37 ± 0.03 | |
| VCO2 at rest (1 min−1) | 0.34 ± 0.280 | .33 ± 0.03 | |
| HYHA class (n) | |||
| II | 15 | n.a. | |
| III | 3 | ||
| Medications (n) | None | ||
| ACE-inhibitors | 15 | ||
| Diuretic | Loop | 13 | |
| Thiazide | 2 | ||
| K spare | 3 | ||
| β-Blockers | 5 | ||
| Aspirin | 9 | ||
| Warfarin | 4 | ||
| Digoxin | 3 | ||
| Statin | 7 | ||
| Amiodarone | 5 | ||
| Calcium antagonist | 1 | ||
Values are given as means ± S.E.M.; CHF, chronic heart failure; LVEF, left ventricular ejection fraction; NYHA, functional classification of the cardiovascular disability according to the New York Heart Association
*
P < 0.05 vs. CHF patients.